Contraceptive injection 'still a good option' despite increased HIV risk

The contraceptive injection should still be offered to women despite new research suggesting it increases the risk of acquiring HIV infection, a GP and sexual health expert has said.

HIV: image shows T-cell infected with the virus (Photo: Science Photo Library)
HIV: image shows T-cell infected with the virus (Photo: Science Photo Library)

A large-scale analysis showed that depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera, was linked to a 40% increase in acquiring HIV infection compared to other forms of contraception, or no contraception. Oral contraceptives did not affect the risk of becoming infected with HIV.

But despite the higher risks, the contraceptive injection remains a good option for many women, Dr Richard Ma, a GP with an interest in sexual health and HIV, told GP.

‘This study needs to be interpreted carefully – it only shows a moderate increase in the risk of acquiring HIV, which is not enough to warrant its withdrawal,’ he said.

Around 8-9% of women using contraception in the UK opt for the injection, according to an NHS Contraceptive Services report.

‘GPs should always talk about STI risk when discussing contraception, particularly with people at high risk. Looking at this study alone, the contraceptive injection shouldn’t be excluded from these discussions,’ Dr Ma said.

Long-term debate

In recent decades, the injection’s link to HIV risk has been hotly debated, but attempts to begin a randomised controlled trial have stalled due to funding issues.

Reasons for the increase in HIV susceptibility are as yet unknown, but biological and behavioural mechanisms have been proposed, such as structural changes to the genital tract. Reduced use of barrier methods could also factor in, although this study adjusted for condom use.

‘Whether the risks of HIV observed in our study would merit complete withdrawal of DMPA needs to be balanced against the known benefits of a highly effective contraceptive,’ the study authors, from the University of California at Berkeley, wrote in The Lancet Infectious Diseases.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women, children and under-18s will not be recommended for routine COVID-19...

GP training: How an audit e-portfolio log entry is assessed

GP training: How an audit e-portfolio log entry is assessed

The second of two articles on audit during GP training looks at how the quality improvement...

GP training: Writing up an audit for your e-portfolio

GP training: Writing up an audit for your e-portfolio

In the first of two articles on how to write up an audit, a typical e-portfolio entry...

UK ups order of 95% effective COVID-19 vaccine by 2m doses

UK ups order of 95% effective COVID-19 vaccine by 2m doses

The UK has increased its order of the 95% effective Moderna COVID-19 vaccine to 7m...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Which COVID-19 vaccines are lined up for roll-out on the NHS?

Which COVID-19 vaccines are lined up for roll-out on the NHS?

As GPs and their teams prepare for delivering a COVID-19 vaccination programme that...